GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Amarin Corporation Plc (AMRN) [hlAlert]

Rating:
Buy AMRN
down 85.28 %

Amarin Corporation Plc (AMRN) rated Buy with price target $5 by MKM Partners

Posted on: Thursday,  Oct 17, 2013  11:25 AM ET by MKM Partners

MKM Partners rated Buy Amarin Corporation Plc (NASDAQ: AMRN) on 10/17/2013. Previously MKM Partners rated Buy Amarin Corporation Plc (NASDAQ: AMRN) on
07/12/2011., when the stock price was $14.20. Since then, Amarin Corporation Plc has lost 85.28% as of 09/08/2015's recent price of $2.09.
If you would have followed the previous MKM Partners's recommendation on AMRN, you would have lost 85.28% of your investment in 1519 days.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin has a range of clinical and preclinical stage compounds to treat central nervous system (CNS) disorders, including Huntington?s disease, myasthenia gravis and Parkinson?s disease. Its cardiovascular programs and non-core CNS programs include AMR101, EN101, Sublingual Apomorphine and AMR 103. The Company's subsidiaries include Amarin Neuroscience Limited, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc, Amarin Finance Limited and Ester Neurosciences Limited.

MKM Partners LLC is an institutional equity trading and research firm. MKM Partners has extensive experience in the agency execution of U.S. and international equity orders. We provide clients with timely and unbiased economic, technical, and fundamental research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/24/2014 11:25 AM Hold
None
1.92 1.75
as of 12/13/2013
1 Week down  -2.25 %
1 Month up  12.33 %
3 Months down  -73.78 %
1 YTD down  -78.61 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/16/2014 11:25 AM Hold
None
2.27 2.50
11/8/2013 11:25 AM Buy
None
1.62 2.50
10/17/2013 11:25 AM Buy
None
2.05 5.00
7/12/2011 11:25 AM Buy
None
14.20 23.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy